プルリに関するコメント

$プルリ(PLUR.US)$
NEWS
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 ...

$プルリ(PLUR.US)$ Pluri Inc: on April 15, Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2)

$プルリ(PLUR.US)$ Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
Benzinga· 1 min ago
Leading biotechnology company, Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, "System and Methods for Immune Cells Ex...